Bruno, 57 years old is in charge of biofertilizers, plant biostimulant, Biocontrole actives and products development. That includes selection of bioactives, their mode of action, product formulation, production scale-up, agronomic testing for efficacy trials. Within OLMIX Group since 2 years and formely at PRP technologies, NOVASEP, PRABIL in products and process development also. OLMIX is developing highly bioactive products from seaweed extracts with a full range of applications depending on their functionalities or activities. Olmix Plant-Care products are integrating some special seaweed extracts together with raw materials coming more and more rom the circular economy. Bruno has a PhD in process engineering and is Engineer in Agronomy.
Justin Teissié, born in 1947, got a degree in engineering from ESPCI (Paris, 1970), a PhD in macromolecular chemistry (Université Paris VI, 1973), a DSc in Biophysics (Université Toulouse, 1979). He was hired by the CNRS in 1973, was a post doc fellow at the Johns Hopkins University (School of Medicine) (Prof T.Y. Tsong)(1979-81). He is DRCE CNRS emeritus since 2012. His field of expertise is dealing with membrane biophysics mostly on the bioelectrochemical aspects. His research is a synergy between development of new hypothesis and concepts and experimental validation through designs of new technologies. He introduced the concept and methodologies of PEF (pulsed electric field) in France in the early 80’s.
Prof. Martin received a bachelors degree in optometry, a masters degree in biomedical engineering and a PhD in biomechanics of contact lenses/biophysics of the anterior eye from the University of New South Wales (Australia). He was awarded the inaugural Medical Foundation Post-Doctoral Fellowship (3 years) to complete postdoctoral training in electrophysiology at the University of Sydney. He then continued the first part of his career in Australia, until 2008, with scientific and academic positions at St Vincent’s Hospital Sydney and the University of Technology Sydney. From 2003-2008 he was an executive board member of the Australian French Association for Science and Technology (AFAS NSW). In 2005 he initiated the Australian network in nanobiotechnology called OzNano2Life, which directly funded postdoctoral researchers in several universities and institutions across Australia and provided the portal for exchanging structured scientific information with nanotechnology institutes in Europe. In 2009 he was awarded a French Chaire d’Excellence to establish a research program in nanobiosciences at the Fondation Nanosciences and the Université Grenoble Alpes. In 2013 he was appointed to the continuing position of Professeur des Universités, Université Grenoble Alpes. He also has an honorary position at the University of Melbourne (Australia). He is the co-author on 11 patents, more than 100 publications and is co-founder in 3 Australian startups. His book on nanobiotechnology published by Springer in 2007 was translated to Russian and published in 2012 by Nauchny Mir, Moscow
Professor Mark Smales is Professor of Industrial Biotechnology in the School of Biosciences at the University of Kent. The group headed by Mark has a number of on-going projects whose objectives are to further advance our understanding of biotechnological products and processes at the fundamental biological or chemical level to enable their manipulation and control for improved (a) biotherapeutic recombinant protein yields and quality, (b) manufacture of gene therapies, (c) re-tuning of cell metabolism via synthetic biology approaches. His group in particular focusses upon the investigation of cultured mammalian cells for the purposes of producing biotherapeutic proteins for the treatment of disease, for the generation of diagnostics and for manufacturing of gene therapies. This includes upstream and downstream bioprocessing and embracing and utilising novel technologies such as genome editing to engineering cell systems and tune them for the desired use. A further aspect of his work is around mRNA translation and its control. He has a particular interest in how both initiation and elongation message specific control is achieved by the cell when under specific stresses, particularly in response to cold-shock.
Mark is Director of the Industrial Biotechnology Centre and a member of the Industrial Biotechnology and Synthetic Biology Research Group.
Dr. Margit Winkler is Elise-Richter fellow at Graz University of Technology and Senior Researcher at the Austrian Center of Industrial Biotechnology. She studied technical chemistry and completed her PhD in Organic Chemistry. As Erwin-Schrödinger fellow, she joined David O’Hagan at the University of St. Andrews. Margit obtained her venia docendi in Biotechnology in 2019. Her research focus is on biocatalysis and she is interested to find and to improve enzymes for challenging chemical transformation and to use them in a biotechnological context.
Agnieszka Saeid graduated from the Department of Chemistry of Wrocław University of Science and Technology (WUST) in 2005. She obtained a Ph.D. (in technical sciences, discipline chemical technology) in 2010 with honors. She was granted a Marie Sklodowska-Curie Actions (MSCA) to participate in Postgraduate School of Industrial Ecology (PSIE) - IndEcol at Norwegian University of Science and Technology in Trondheim. She has published over 114 papers, including 64 papers in world-known peer-reviewed scientific journals from JCR list, ), 16 chapters in books, including 12 chapters published by Wiley (4), CRC Press (1), Studium Press LLC (1), Elsevier (3), NOVA Science (2) and InTech Open (1)). Her works were cited more than 390 times and h-index: 13. She is the author of 4 patents and 3 patent application. She cooperates with many universities in the field of multidisciplinary projects.